Skip to Main Content

Good morning, everyone, and welcome to another working week. We hope the weekend respite was invigorating and relaxing, because that oh-so-familiar routine of meetings, deadlines, phone calls, and memos has returned. Did we forget something? The world, after all, keeps on spinning. To attain some equilibrium, yes, we are firing up the coffee kettle for a few cups of stimulation. Our choice today is a blend of cranberry and white chocolate. Meanwhile, here are some tidbits to help you get started. Hope your day is wonderful and productive. And of course, do keep in touch …

Gilead Sciences (GILD) hired Roche (RHHBY) chief executive Daniel O’Day to run the company amid pressure to revive sales as its hepatitis C franchise declines and to recover from a disappointing deal for a CAR-T treatment, The Wall Street Journal reports. Sales of the Yescarta CAR-T medicine have so far been meager, while O’Day has a record turning drugs into big sellers. For this reason, O’Day, who replaces John Milligan on March 1, should be viewed favorably by Gilead investors, according to STAT. Roche, meanwhile, elevated Bill Anderson, who heads the Genentech unit, to oversee its pharma business.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!